The American Society of Clinical Oncology said it opposes “right-to-try” laws that allow terminally ill patients to request access to investigational drugs directly from manufacturers, bypassing a layer of review, where FDA assesses the available data to review and benefits of the treatment on behalf of the patient.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
